US biotech bounces back
OVER the past three years, US biotech companies have absorbed hard knocks like a punch-drunk boxer, sending stock prices into a dizzying descent. But the market has rallied during 2003, proving you can never count biotech out. Corporate scandals, clinical trial failures, fewer drug approvals, deflated expectations of genome-inspired breakthroughs and a turbulent world economic …